Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, tolebrutinib
Sanofi says tolebrutinib drug delayed progressive MS by 31%
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study Following Earlier Flops
The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of back-to-back failures in which tolebrutinib was unable to improve relapse rates in patients with relapsing MS.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was able to delay the time to six-month disability progression by 31% compared to placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.
Cleveland Clinic researcher advises Sanofi on multiple sclerosis drug that slows disease’s progression
Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing secondary progressive MS, according to data from a late stage trial presented Friday, Sept. 20, at a research congress in Copenhagen. The results confirm topline findings published on Sept. 2.
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
FRANKFURT, Sept 20 (Reuters) -
Sanofi
(SASY.PA), opens new tab said ... summary that the late-stage trial with the drug candidate
tolebrutinib
was successful. That mitigated a setback announced ...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi
is pursuing several opportunities in ... 2025 margin targets last October to boost drug development spending.
Tolebrutinib
, from the $3.7 billion takeover of Principia in 2020, belongs ...
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Sanofi’s eyes approval after MS therapy slows disease progression by 31%
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.
Multiple Sclerosis News Today
8h
ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...
1h
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
FierceBiotech
3d
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
1951 kidnap victim found
Alabama mass shooting
Daylight saving time
Visits US ammunition plant
California plastic bag ban
No govt. shutdown for now
Robinson loses key staff
Trump to campaign in MI
Economic speech this week
Dolphins legend Morris dies
Israeli strikes in Lebanon
To meet Vietnamese pres
San Francisco homelessness
SpaceX plans Mars missions
Ga. suspect's mom indicted
No. 1 at box office again
Free COVID-19 tests
Donlon's homes searched
Released after guilty plea
Former WA governor dies
Drug price challenge revived
ISR raids Al Jazeera office
TN abortion law blocked
Boeing defense chief exits
SC 1st execution in 13 years
CA firefighter held for arson
Biden hosts 'Quad' summit
Iran coal mine blast
PM Modi visits US
CA bill to protect kids online
Sesame Place suit verdict
J&J unit files for bankruptcy
Feedback